שווי מתואם לחוב ומזומנים Morphic Holding Corp (MORF)

Morphic Holding, Inc. (MORF) is establishing close partnerships with CDMO contractors to launch mass production of drugs, creating redundant capacities. Business growth is fueled by a merger with Eli Lilly and the development of an innovative oral treatment for Crohn's disease. The company's pricing evolution, where the Enterprise Value equals , reflects the specifics of a model based on the full delegation of synthesis and testing to external laboratories.

The selection of the issuer is based on a multiples analysis, where the key metric is the calculation of the total business buyout cost via the sum of market capitalization and debt minus liquid assets. For Morphic Holding, Inc. (MORF), which is developing innovative oral drugs for intestinal inflammation, the total capital indicator reflects the market acquisition price of the company, accounting for its debt load during an active growth phase.